"Today, we are pleased to announce the conclusion of a long-term supply agreement with the Serum Institute of India for the COVID-19 vaccines, to access two vaccine products through technology transfer from AstraZeneca and Novavax", Sputnik quoted Fore as saying at a COVAX press briefing.
NEW YORK: India's Serum Institute will be supplying 1.1 billion doses of coronavirus vaccines developed by AstraZeneca and Novavax to around 100 countries for approximately USD 3 per dose for the low and lower-middle-income countries, said Henrietta Fore, United Nations International Children's Emergency Fund (UNICEF) chief, on Wednesday.
"Today, we are pleased to announce the conclusion of a long-term supply agreement with the Serum Institute of India for the COVID-19 vaccines, to access two vaccine products through technology transfer from AstraZeneca and Novavax," Sputnik quoted Fore as saying at a COVAX press briefing.
She further said, "UNICEF, along with our procurement partners including PAHO, will have access to up to 1.1 billion doses of vaccines for around 100 countries for approximately USD 3 a dose for the low- and lower-middle income countries."
India on January 16 began its mammoth coronavirus vaccine rollout by administering 207,229 shots on the first day with the help of hundreds of thousands of health workers who were trained and assisted by the UN agencies.
The Central government has introduced an application named CoWIN (Covid Vaccine Intelligence Work) to monitor the entire vaccination process.
Two vaccines--Covaxin and Covishield-- have received Emergency Use Authorisation (EAU) after going through established safety and immunogenicity in a well-prescribed regulatory process and these will be administered during the vaccination drive.
Last week, the Ministry of External Affairs had stated that India has gifted over 55 lakh doses of COVID-19 vaccine to neighbouring countries.
Addressing a weekly briefing, External Affairs Ministry spokesperson Anurag Srivastava on Thursday said India plans to gift vaccines doses to Oman, CARICOM countries, Nicaragua, Pacific Island states.
He further said that New Delhi plans to supply 1 crore or 10 million vaccine doses to Africa and 10 lakh to United Nations health workers under GAVI's (Global Alliance for Vaccines and Immunisation) COVAX facility.
Source - The Economic Times
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
SII CEO Adar Poonawalla & Director Prakash Kumar Singh call on Hon'ble President of India Smt. Droupadi Murmu
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.